An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy.

Abstract:

:Methylphenidate (MPH) is one of the most commonly prescribed medications to treat attention deficit hyperactivity disorder (ADHD). Despite the elevated rates of ADHD in children with epilepsy, few studies have examined the use of MPH in this population. Case reports have warned about new-onset seizures in patients treated with MPH, and drug-drug interactions between MPH and antiepileptic drugs (AEDs), as well as antidepressants. However, retrospective chart reviews, open-label trials and controlled trials of MPH in patients with epilepsy and ADHD have noted significant improvements in ADHD symptoms without an exacerbation of seizures or an adverse effect on AED serum levels. This paper reviews the chemistry and mechanisms of action of MPH, as well as preclinical, premarketing clinical trials and postmarketing data relevant to its use in patients with ADHD and epilepsy.

authors

Baptista-Neto L,Dodds A,Rao S,Whitney J,Torres A,Gonzalez-Heydrich J

doi

10.1517/13543784.17.1.77

subject

Has Abstract

pub_date

2008-01-01 00:00:00

pages

77-84

issue

1

eissn

1354-3784

issn

1744-7658

journal_volume

17

pub_type

杂志文章,评审
  • Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.

    abstract::BCR-ABL, a constitutively active tyrosine kinase, causes chronic myeloid leukaemia (CML). Rational development of drugs targeting BCR-ABL has significantly improved the treatment of CML. Imatinib (a BCR-ABL tyrosine kinase inhibitor) produces haematological and cytogenetic remissions across all phases of CML and is th...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.5.679

    authors: Jabbour E,Cortes J,Kantarjian H

    更新日期:2007-05-01 00:00:00

  • Sorafenib in locally advanced or metastatic breast cancer.

    abstract:INTRODUCTION:Sorafenib is an oral multikinase inhibitor with anti-angiogenic and anti-proliferative activity that is indicated for use in hepatocellular and renal cell carcinomas. Sorafenib is being developed in a number of solid tumors, including breast cancer (BC). AREAS COVERED:A series of four randomized, double-b...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.689824

    authors: Gradishar WJ

    更新日期:2012-08-01 00:00:00

  • Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.

    abstract:INTRODUCTION:Frontline chemotherapy is successful against chronic lymphocytic leukemia (CLL), but results in untoward toxicity. Further, prognostic factors, cytogenetic anomalies, and compensatory cellular signaling lead to therapy resistance or disease relapse. Therefore, for the past few years, development of targete...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1312338

    authors: Vangapandu HV,Jain N,Gandhi V

    更新日期:2017-05-01 00:00:00

  • New antithrombotic drugs on the horizon.

    abstract::Venous and arterial thromboembolism are a major cause for morbidity and mortality. The list of established drugs for the prevention of thrombus formation and embolisation includes heparins, hirudin and derivatives, aspirin, ADP and glycoprotein IIb/IIIa receptor antagonists, as well as vitamin K antagonists. Several l...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.5.781

    authors: Ruef J,Katus HA

    更新日期:2003-05-01 00:00:00

  • Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.

    abstract:INTRODUCTION:Crizotinib is a first-in-class ALK tyrosine kinase inhibitor (TKI), which has proven its superiority over standard platinum-based chemotherapy for the first-line therapy of ALK-rearranged non-small cell lung cancer (NSCLC) patients. The development of acquired resistance to crizotinib represents an ongoing...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1324572

    authors: Karachaliou N,Santarpia M,Gonzalez Cao M,Teixido C,Sosa AE,Berenguer J,Rodriguez Capote A,Altavilla G,Rosell R

    更新日期:2017-06-01 00:00:00

  • Recent advances in the management of adult myositis.

    abstract::Standard drug therapy of adult polymyositis, dermatomyositis and inclusion body myositis includes high-dose corticosteroids and cytotoxic drugs (methotrexate, azathioprine (AZA) and cyclophosphamide). Recent data are in favour of the early introduction of a cytotoxic or immunomodulating drug in addition to corticoster...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.7.1265

    authors: Fam AG

    更新日期:2001-07-01 00:00:00

  • Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.

    abstract::Introduction: The conventional management of most patients with metastatic urothelial carcinoma (UC) is platinum-based chemotherapy followed by immunotherapy. Erdafitinib is an option in post-platinum patients with activating mutations in fibroblast growth factor receptor (FGFR)-3 and -2. Salvage therapy with taxanes ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2019.1667332

    authors: McGregor BA,Sonpavde G

    更新日期:2019-10-01 00:00:00

  • A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects.

    abstract::Background: To compare the pharmacokinetic (PK) profile, safety, and immunogenicity between golimumab and the biosimilar BAT2506 in healthy Chinese male subjects. Research design and methods: A total of 180 healthy male subjects were recruited for this randomized, double-blinded, single-dose, parallel study. They rece...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2021.1851364

    authors: Wu M,Sun J,Wu D,Xu J,Wei J,Wang Z,Yu J,Li S,Zhang H,Ding Y

    更新日期:2021-01-01 00:00:00

  • Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol).

    abstract:BACKGROUND:Today, propofol or 2,6-diisopropylphenol is the anesthetic mainly used for monitored anesthetic care sedation and during intravenous anesthesia. The formulation, a lipid macroemulsion, shows several disadvantages. Therefore, during the past years considerable scientific effort has been undertaken to find eit...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903193063

    authors: Fechner J,Ihmsen H,Jeleazcov C,Schüttler J

    更新日期:2009-10-01 00:00:00

  • P2X7 receptor antagonism in the treatment of cancers.

    abstract::ATP-gated P2X7 receptors (P2X7) make a unique family of extracellular ATP-activated plasma membrane ion channels expressed in haematopoietic and epithelial cells. They have been extensively studied in immune cells where their activation leads to the rapid release of pro-inflammatory cytokines and the initiation of the...

    journal_title:Expert opinion on investigational drugs

    pub_type: 社论

    doi:10.1517/13543784.2011.583918

    authors: Roger S,Pelegrin P

    更新日期:2011-07-01 00:00:00

  • Urokinase receptor antagonists: novel agents for the treatment of cancer.

    abstract::The interaction between the urokinase receptor (uPAR) and its ligand urokinase (uPA) mediates phenomena such as tissue remodelling, chemotaxis, tumour invasion, dissemination, proliferation, and angiogenesis. The broad-spectrum of biological processes that the uPA/uPAR interaction plays a role in has led researchers t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.3.391

    authors: Weidle UH,König B

    更新日期:1998-03-01 00:00:00

  • Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.

    abstract::Heat shock proteins are vital to cell survival under conditions of stress. They bind client proteins to assist in protein stabilization, translocation of polypeptides across cell membranes and recovery of proteins from aggregates. Heat shock protein inhibitors are a diverse group of novel agents that have been demonst...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903158934

    authors: Hanson BE,Vesole DH

    更新日期:2009-09-01 00:00:00

  • Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases.

    abstract::Insulin-sensitizing thiazolidinediones (TZDs) correct a root cause of type 2 diabetes and potentially other diseases of metabolic dysfunction, including conditions ranging from oncologic, inflammatory, and neurodegenerative diseases. Importantly, compounds with this mode of action can modify disease progression, as op...

    journal_title:Expert opinion on investigational drugs

    pub_type: 社论,评审

    doi:10.1517/13543784.2013.839659

    authors: Colca JR,Tanis SP,McDonald WG,Kletzien RF

    更新日期:2014-01-01 00:00:00

  • Olaparib for the treatment of breast cancer.

    abstract:INTRODUCTION:Basal-like breast cancer is characterized by being triple negative and aggressive. Defects in DNA repair is a promising therapeutic target as BRCA alterations are found in 11 to 42% of these tumors, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors exploit this de...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1318847

    authors: Robert M,Frenel JS,Gourmelon C,Patsouris A,Augereau P,Campone M

    更新日期:2017-06-01 00:00:00

  • New microtubule-inhibiting anticancer agents.

    abstract:UNLABELLED:IMPORTANCE OF THIS FIELD: Microtubule-inhibiting drugs are among the most commonly prescribed agents in the combat against cancer, though the clinical use of these drugs is limited by acquired resistance, risk of hypersensitivity reactions and intolerable toxicity. With progress in our understanding of cytos...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903571631

    authors: Chen SM,Meng LH,Ding J

    更新日期:2010-03-01 00:00:00

  • Non-anticoagulant derivatives of heparin for the management of asthma: distant dream or close reality?

    abstract:INTRODUCTION:Approximately 300 million people worldwide are currently affected by asthma. Improvements in the understanding of the mechanisms involved in such inflammatory airway disorders has led to the recognition of new therapeutic approaches. Heparin, a widely used anticoagulant, has been shown to be beneficial in ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.866092

    authors: Shastri MD,Peterson GM,Stewart N,Sohal SS,Patel RP

    更新日期:2014-03-01 00:00:00

  • The potential of endothelin antagonism as a therapeutic approach.

    abstract::Endothelin (ET) is a pivotal physiological regulator of blood pressure through its effects on blood vessels, heart, lung and kidneys, and the ET system can be overactive in disorders such as pulmonary hypertension, heart failure and renal disease. Such observations stimulated interest among scientists and pharmaceutic...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.11.1419

    authors: Benigni A,Perico N,Remuzzi G

    更新日期:2004-11-01 00:00:00

  • Drug delivery across the skin.

    abstract::Since the introduction of the first through the skin (TTS) therapeutic in 1980, a total of 34 TTS products have been marketed and numerous drugs have been tested by more than 50 commercial organisations for their suitability for TTS delivery. Most of the agents which have been tested have had low molecular weights, du...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.12.1887

    authors: Cevc G

    更新日期:1997-12-01 00:00:00

  • Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial.

    abstract:BACKGROUND:Age-related macular degeneration is the leading cause of blindness among elderly individuals in industrialized countries. New drugs and advanced concepts for the treatment of dry AMD (dAMD) are needed. A new approach is the application of intravenous infusions of prostaglandin E1. OBJECTIVE:The aim of this ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1517/13543784.2013.794782

    authors: Augustin AJ,Diehm C,Grieger F,Bentz J

    更新日期:2013-07-01 00:00:00

  • Dronedarone: an amiodarone analogue.

    abstract::Of the antiarrhythmic drugs in current use, amiodarone is one of the most effective and is associated with a comparatively low risk of drug-induced pro-arrhythmia, probably due to its multiple pharmacological actions on cardiac ion channels and receptors. However, amiodarone is associated with significant extra-cardia...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.4.415

    authors: Doggrell SA,Hancox JC

    更新日期:2004-04-01 00:00:00

  • Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition.

    abstract:INTRODUCTION:Cardiovascular disease is the leading cause of death worldwide, accounting for 30% of all deaths, with elevated blood pressure probably the most important modifiable risk factor. Worldwide, elevated blood pressure is estimated to cause 7.5 million deaths, about 12.8% of the total of all annual deaths. New ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2013.797962

    authors: Segura J,Salazar J,Ruilope LM

    更新日期:2013-07-01 00:00:00

  • Emerging therapeutic interventions against noise-induced hearing loss.

    abstract:INTRODUCTION:Noise-induced hearing loss (NIHL) due to industrial, military, and recreational noise exposure is a major, but also potentially preventable cause of acquired hearing loss. For the United States it is estimated that 26 million people (15% of the population) between the ages of 20 and 69 have a high-frequenc...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1269171

    authors: Sha SH,Schacht J

    更新日期:2017-01-01 00:00:00

  • A novel CXCR4 antagonist for hematopoietic stem cell mobilization.

    abstract:BACKGROUND:Hematopoietic stem cell (HSC) transplantation is a treatment option for hematological malignancies. Current mobilization regimes frequently result in inadequate numbers of HSC for transplant therefore alternative methods of mobilization are required. OBJECTIVE:The chemokine receptor CXCR4 and ligand SDF-1 a...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.11.1749

    authors: Fricker SP

    更新日期:2008-11-01 00:00:00

  • An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

    abstract:INTRODUCTION:Sepsis with Bacillus anthracis infection has a very high mortality rate despite appropriate antibiotic and supportive therapies. Over the past 15 years, recent outbreaks in the US and in Europe, coupled with anthrax's bioterrorism weapon potential, have stimulated efforts to develop adjunctive therapies to...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2015.1041587

    authors: Ohanjanian L,Remy KE,Li Y,Cui X,Eichacker PQ

    更新日期:2015-01-01 00:00:00

  • Is everolimus useful in preventing allograft rejection and vasculopathy after heart transplant?

    abstract::The main cause of illness and death after the first year of heart transplantation is vasculopathy of the cardiac allograft, probably initiated by early immunological and non-immunological endothelial damage. The incidence of multiple episodes of grade 3A rejection 6 months after primary heart transplantation was lower...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.13.2.161

    authors: Doggrell SA

    更新日期:2004-02-01 00:00:00

  • Investigational drugs for eating disorders.

    abstract::The eating disorders anorexia nervosa, bulimia nervosa and binge eating disorder are common, significant public health problems which are treated with nutritional, psychotherapeutic and pharmacological interventions. A number of drugs (mostly antidepressant drugs) are currently used in their treatment to some benefit,...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.3.491

    authors: Crow S,Brown E

    更新日期:2003-03-01 00:00:00

  • Current and emerging investigational medical therapies for the treatment of overactive bladder.

    abstract::Overactive bladder (OAB) is a chronic distressing condition characterised by urinary urgency with or without urge incontinence, usually with frequency (voiding at least eight times daily) and nocturia. It affects millions of people worldwide independent of age, sex and race. The prevalence increases with age and is re...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.9.1017

    authors: Tiwari A,Naruganahalli KS

    更新日期:2006-09-01 00:00:00

  • LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action.

    abstract::Two classes of luteinising hormone-releasing hormone (LHRH) analogues have been developed so far to be used for oncological therapies: LHRH agonists and antagonists. LHRH agonists are widely and successfully used for the management of steroid-dependent malignancies. Chronic administrations of these compounds result in...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.4.709

    authors: Limonta P,Montagnani Marelli M,Moretti RM

    更新日期:2001-04-01 00:00:00

  • Therapies in development for the treatment of migraine.

    abstract::While oral formulations of agonists at the serotonin (5-HT) receptor subdivisions 5-HT(1B/1D)--the "triptan" class of drugs--dominate the market for migraine therapy and while still more triptans are under development, recent research efforts have also explored other pharmacological avenues, which are mostly based on ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.12.1813

    authors: Mucke H

    更新日期:2002-12-01 00:00:00

  • Alpha-lipoic acid, an anti-obesity agent?

    abstract::Obesity shortens life expectancy and is a risk factor for hypertension and Type 2 diabetes. When added to the standard chow of Sprague-Dawley or Otsuka Long-Evans Tokushima Fatty rats, alpha-lipoic acid (0.5% weight/weight) reduced body weight and food intake. Alpha-lipoic acid also increased whole-body energy expendi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.12.1641

    authors: Doggrell SA

    更新日期:2004-12-01 00:00:00